herbimycin

herbicidal antibiotic produced by Streptomyces sp.; see also herbimycin B; structure for herbimycin A in second source

Also Known As:

NSC 305978; geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)-; herbimycin A; ((4E,6E,8S,9S,10E,12S,13R,14S,16S,17R)-8,13,14,17-tetramethoxy-4,10,12,16-tetramethyl-3,20,22-trioxo-2-azabicyclo(16.3.1)docosa-4,6,10,18,21-pentaen-9-yl) carbamate

Networked: 100 relevant articles (4 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Naoe, T: 3 articles (08/2002 - 03/2000)
2.	Saito, H: 3 articles (08/2002 - 03/2000)
3.	Ueda, R: 3 articles (08/2002 - 03/2000)
4.	Yamamoto, Y: 3 articles (08/2002 - 03/2000)
5.	Choi, Moon Gi: 2 articles (10/2015 - 12/2014)
6.	Ihm, Sung-Hee: 2 articles (10/2015 - 12/2014)
7.	Kang, Jun Goo: 2 articles (10/2015 - 12/2014)
8.	Kim, Chul Sik: 2 articles (10/2015 - 12/2014)
9.	Kim, Si Hyoung: 2 articles (10/2015 - 12/2014)
10.	Lee, Seong Jin: 2 articles (10/2015 - 12/2014)

Related Diseases

1.	Leukemia 03/03/1995 - "These results suggest that herbimycin A and related compounds may be useful for the treatment of Ph1-positive leukemia. " 09/01/1992 - "The present study indicates that herbimycin A is a beneficial agent for the investigation of the role of the bcr-abl gene in Ph1-positive leukemias and further suggests that the development of agents inhibiting the bcr-abl gene product may offer a new therapeutic potential for Ph1-positive leukemias." 08/01/2002 - "As a therapeutic approach, we previously reported that herbimycin A (HA) inhibited the growth of tandemly duplicated FLT3 (TDFLT3)-transformed cells (Leukemia 2000; 14: 374). " 08/01/2001 - "In mice transplanted with transformed 32D cells, the administration of herbimycin A completely prevented leukemia progression. " 03/01/2000 - "In mice transplanted with the transformed 32D cells, the administration of herbimycin A prolonged the latency of disease or completely prevented leukemia, depending on the number of cells inoculated and schedule of drug administration. "
2.	Hypoxia (Hypoxemia) 12/19/2003 - "Herbimycin A induces sympathetic neuron survival and protects against hypoxia." 03/01/2003 - "The herbimycin A-induced increase in HSP-70i protected cells from hypoxia injury." 12/19/2003 - "In the presence of NGF and 100 ng/ml herbimycin, 81% of the neurons survived hypoxia. " 06/01/1995 - "These results suggest that PKC and herbimycin-sensitive tyrosine kinase may serve as negative regulators of the hypoxia-activated signal transduction pathway that leads to the induction of VEGF expression. " 06/01/1995 - "Furthermore, chronic exposure to TPA or treatment with herbimycin A results in the enhancement of the hypoxia-mediated increase in VEGF mRNA levels. "
3.	Neoplasms (Cancer) 11/01/1994 - "injection inhibited tumor formation and significantly prolonged survival time, and further, in mice inoculated with 1 x 10(4) cells, herbimycin A completely suppressed the in vivo growth of transformant FDC-P2 cells and brought about a complete remission. " 08/01/2007 - "As expected, herbimycin A treatment reduced tumor growth as assessed both by tumor volume measurement and bioluminescent imaging. " 07/01/1996 - "During 2-day treatment with herbimycin A, no changes were observed in tumor size. " 09/01/1989 - "We have examined the suppressive effect of herbimycin A on the reduction of gap-junctional intercellular communication that is induced by a tumor-promoting phorbol ester in 3T3-L1 cells. " 09/01/1989 - "Herbimycin A suppresses the reduction of gap-junctional intercellular communication induced by tumor-promoting phorbol ester in 3T3-L1 cells."
4.	Reperfusion Injury 11/01/2000 - "Protective effects of herbimycin A on hepatic reperfusion injury."
5.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/01/1994 - "Herbimycin A, an inhibitor of tyrosine kinase, preferentially inhibited the growth of Ph1-positive acute lymphoid leukemia (ALL) cell lines, as well as Ph1-positive chronic myeloid leukemia (CML) cell lines. " 10/01/1992 - "Herbimycin A, a selective inhibitor of tyrosine kinase activity, induced differentiation of leukemia cells isolated from Philadelphia chromosome-positive chronic myelogenous leukemia patients. " 07/01/2000 - "p210bcr-abl, a protein expressed in chronic myelogenous leukemia, is functionally inhibited by the benzoquinone ansamycin herbimycin A. " 10/01/2003 - "In the mid 1980s, it was found that the benzoquinone ansamycin antibiotics (herbimycin A, geldanamycin, and macbecin) reversed v-Src transformed cells to normal phenotypes, and Bcr-abl was subsequently suggested to be the molecular target for the treatment of chronic myelogenous leukemia through a study using herbimycin A for its selective antioncogenic activity. " 09/01/1992 - "In Philadelphia chromosome (Ph1)-positive leukemias such as chronic myelogenous leukemia (CML) and Ph1-positive acute lymphoblastic leukemia (ALL), both of which express bcr-abl fused gene products (P210bcr-abl or P190bcr-abl protein kinase) with augmented tyrosine kinase activities, herbimycin A markedly inhibited the in vitro growth of the Ph1-positive ALL cells and the leukemic cells derived from CML blast crisis. "

Related Drugs and Biologics

1.	Protein-Tyrosine Kinases (Tyrosine Kinase)
2.	Genistein
3.	lavendustin A
4.	Tyrphostins
5.	Trypan Blue
6.	Proteins (Proteins, Gene)
7.	Tyrosine (L-Tyrosine)
8.	Anti-Bacterial Agents (Antibiotics)
9.	geldanamycin
10.	Rifabutin (Ansamycin)

Related Therapies and Procedures

1.	Therapeutics
2.	Subcutaneous Injections